John Leyden

1 POSTS 0 COMMENTS
John Leyden FCA is Chief Executive of Carbon Accountancy Limited www.carbonacccountancy.co.uk. He was shortlisted for the Finance Director of the Year Awards 2012 by the ICAEW. He spent seven years at KPMG before starting Carbon Accountancy, which prides itself on outstanding client service and meeting client needs through trust and dedication. John specialises in business advice, tax planning, corporate finance, due diligence and share option schemes.

Latest articles

Dr Harry Destecroix of Ziylo wins 2019 Pharmaceutical Industry Network Group Innovation Award

Biotech leader wins PING Innovation Award 2019

Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...
NICE recommend funding for Spinraza

NICE recommend funding for Spinraza for spinal muscular atrophy

The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS). The positive recommendation, subject to...
Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

New data from Novel START trial accepted for presentation

New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
new migraine data for Aimovig presented by Novartis

Novartis presents new migraine data for Aimovig®▼ (erenumab)

Novartis presents new migraine data for Aimovig®▼ (erenumab) demonstrating sustained efficacy to 52 weeks. Novartis has announced that new data from two follow-up studies of...
Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

New data from Novel START trial accepted for presentation

New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...

Top 5 R&D hubs in the UK

Read this cover story in the June issue of Pf Magazine here.    Join us on a tour of inspirational research and development centres. ...
Dr Harry Destecroix of Ziylo wins 2019 Pharmaceutical Industry Network Group Innovation Award

Biotech leader wins PING Innovation Award 2019

Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...